A Study to Assess the Efficacy and Safety of HRG2005 Inhalation in Patients With Moderate to Severe Chronic Obstructive Pulmonary Disease

NCT ID: NCT06035393

Last Updated: 2025-12-22

Basic Information

• Recruitment Status: TERMINATED
• Clinical Phase: PHASE2
• Total Enrollment: 82 participants
• Study Classification: INTERVENTIONAL
• Study Start Date: 2024-01-15
• Study Completion Date: 2025-02-17

Brief Summary

This is a randomized, double blind, double dummy, active-controlled, parallel-group study to assess the efficacy and Safety of HRG2005 inhalation in patients with moderate to severe chronic obstructive pulmonary disease. Approximately 200 patients with moderate to severe COPD will be randomized into the study.

Conditions

Chronic Obstructive Pulmonary Disease

Study Design

• Allocation Method: RANDOMIZED
• Intervention Model: PARALLEL
• Primary Study Purpose: TREATMENT
• Blinding Strategy: TRIPLE

Study Groups

Treatment group A

Drug1 dose 1+Drug 3

Group Type: EXPERIMENTAL

HRG2005 inhalation

Intervention Type: DRUG

Drug 1: dose 1; dose 2; dose 3

Placebo to match Indacaterol Maleate and Glycopyrronium Bromide Powder for inhalation

Intervention Type: DRUG

Drug 3

Treatment group B

Drug1 dose 2+Drug 2+Drug 3

Group Type: EXPERIMENTAL

HRG2005 inhalation

Intervention Type: DRUG

Drug 1: dose 1; dose 2; dose 3

Placebo to match HRG2005 inhalation

Intervention Type: DRUG

Drug 2

Placebo to match Indacaterol Maleate and Glycopyrronium Bromide Powder for inhalation

Intervention Type: DRUG

Drug 3

Treatment group C

Drug1 dose 3+Drug 2+Drug 3

Group Type: EXPERIMENTAL

HRG2005 inhalation

Intervention Type: DRUG

Drug 1: dose 1; dose 2; dose 3

Placebo to match HRG2005 inhalation

Intervention Type: DRUG

Drug 2

Placebo to match Indacaterol Maleate and Glycopyrronium Bromide Powder for inhalation

Intervention Type: DRUG

Drug 3

Treatment group D

Drug 2+Drug 4

Group Type: OTHER

Placebo to match HRG2005 inhalation

Intervention Type: DRUG

Drug 2

Indacaterol Maleate and Glycopyrronium Bromide Powder for inhalation

Intervention Type: DRUG

Drug 4

Interventions

HRG2005 inhalation

Drug 1: dose 1; dose 2; dose 3

Intervention Type: DRUG

Placebo to match HRG2005 inhalation

Drug 2

Intervention Type: DRUG

Placebo to match Indacaterol Maleate and Glycopyrronium Bromide Powder for inhalation

Drug 3

Intervention Type: DRUG

Indacaterol Maleate and Glycopyrronium Bromide Powder for inhalation

Drug 4

Intervention Type: DRUG

Eligibility Criteria

Inclusion Criteria

1. Able and willing to provide written informed consent and to comply with the study protocol;

2. Subjects 40 years of age or older (inclusive), Male or female subjects;

3. Subjects with an established clinical history of COPD;

4. A post-bronchodilator FEV1/FVC ratio must be <0.7 at Screening and FEV1 must be <80% and ≥30% predicted normal at pre-randomization;

5. a documented history of ≥ 2 moderate or ≥ 1 severe COPD exacerbation in the previous 12 months;

6. Tobacco Use: Current or former smokers with a history of at least 10 pack-years of cigarette smoking;

7. A score of ≥10 on the COPD Assessment Test (CAT) at pre-randomization.

Exclusion Criteria

1. Subjects who required systemic corticosteroids or antibiotics or hospitalized due to poorly controlled COPD or who had lower respiratory tract infections that required antibiotics within 4 weeks prior to Screening to pre-randomization;

2. Subjects who had respiratory tract infections that required antibiotics within 2 weeks prior to Screening to pre-randomization;

3. Subjects with other respiratory or respiratory related diseases, including but not limited to asthma, active tuberculosis, lung cancer, interstitial pulmonary disease, α1-antitrypsin deficiency, pulmonary heart disease, clinically significant pulmonary hypertension, clinically significant bronchiectasis, or other active pulmonary disease;

4. Subjects with lung volume reduction surgery within the 12 months prior to Screening;

5. Subjects who have Other known serious medical conditions；

6. Subjects receiving oxygen therapy required for greater than 15 hours a day;

7. Clinically significant electrocardiogram abnormality；

8. Subjects with significant laboratory abnormality at screening；

9. Suspected allergy to any ingredient in the study drug;

10. Participation in clinical trials of any drug or medical device (except for screening failures) within 4 weeks before screening, or within 5 half-lives of the drug at screening (whichever is longer);

11. Pregnant or lactating females;

12. History of drug abuse within one year before screening

13. Other conditions judged by the investigator to be not suitable to participate in the trial.

• Minimum Eligible Age: 40 Years
• Eligible Sex: ALL
• Accepts Healthy Volunteers: No

Sponsors

Jiangsu HengRui Medicine Co., Ltd.

INDUSTRY

Sponsor Role: lead

Responsible Party

Responsibility Role: SPONSOR

Locations

Peking University Third Hospital

Beijing, Beijing Municipality, China

Countries

China

Other Identifiers

HRG2005-201

Identifier Type: -

Identifier Source: org_study_id